In one paragraphArticle in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
13 authors.
Keisuke WatanabeDivision of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center Japan, Tokyo, Japan.ORCID http://orcid.org/0000-0002-6539-2549 Yue YanDepartment of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kazuhiro KumagaiDepartment of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yasuhiro KojimaLaboratory of Computational Life Science, National Cancer Center, Tokyo, Japan.
Yuka MaedaDivision of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center Japan, Tokyo, Japan.
Takuma KatoDepartment of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Funding
Japan Agency for Medical Research and Development (AMED) 16cm0106301h0001Japan Agency for Medical Research and Development (AMED) 19ae0101074s0401Japan Agency for Medical Research and Development (AMED) 22ama221301h0001Japan Agency for Medical Research and Development (AMED) 22zf0127009h0001Japan Agency for Medical Research and Development (AMED) 24ama221327h0002Japan Agency for Medical Research and Development (AMED) 24ym0126135h0001
6 · The paper itselfAbstract
Indexed as
CD8-Positive T-LymphocytesImidazolesImmunologic MemoryLymphocyte Specific Protein Tyrosine Kinase p56(lck)Memory T CellsPhosphatidylinositol 3-KinasesPyridazinesAnimalsCell DifferentiationCell Line, TumorFemaleHumansLymphocyte ActivationMiceMice, Inbred C57BLProtein Kinase InhibitorsImidazolesLymphocyte Specific Protein Tyrosine Kinase p56(lck)Phosphatidylinositol 3-KinasesponatinibProtein Kinase InhibitorsPyridazinesReceptors, Chimeric AntigenTyrosine Kinase Inhibitors
Identifiers
PMID41946709
PMCPMC13233839
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390